Inhibition of angiogenesis- and inflammation-inducing factors in human colon cancer cells in vitro and in ovo by free and nanoparticle-encapsulated redox dye, DCPIP

Journal of Nanobiotechnology

Volumn 8, Issue , 2010, Pages

  Mondalek, Fadee G ^a,c   Ponnurangam, Sivapriya ^a   Govind, Janita ^a   Houchen, Courtney ^b   Anant, Shrikant ^b   Pantazis, Panayotis ^a,c   Ramanujam, Rama P ^a,c  

^a Swaasth Inc   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c ADNA Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS; ANTI-INFLAMMATION; APOPTOSIS; CASPASE-3; CELL LINES; CELLULAR FACTORS; CHICK CHORIOALLANTOIC MEMBRANE; GROWTH FACTOR; HUMAN COLON CANCER; HUMAN COLON CANCER CELLS; IN-VITRO; LONG LASTING; NUCLEAR FACTORS; SYNTHETIC NANOPARTICLES;

BIOCHEMISTRY; CELL CULTURE; CELL DEATH; CELL PROLIFERATION; IMMUNOLOGY; PATHOLOGY;

NANOPARTICLES;

2,6 DICHLOROPHENOLINDOPHENOL; CASPASE 3; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; VASCULOTROPIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL PROLIFERATION; CELL STRAIN HCT116; CHICK; CHORIOALLANTOIS; DRUG ACTIVITY; DRUG EFFECT; ENZYME DEGRADATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN;

SPONDIAS PURPUREA;

EID: 77954550250     PISSN: None     EISSN: 14773155     Source Type: Journal    
DOI: 10.1186/1477-3155-8-17     Document Type: Article

References (62)

1. Chien MH, Ku CC, Johansson G, Chen MW, Hsiao M, Su JL, Inoue H, Hua KT, Wei LH, Kuo ML. Vascular endothelial growth factor-C (VEGF-C) promotes angiogenesis by induction of COX-2 in leukemic cells via the VEGF-R3/JNK/AP-1 pathway. Carcinogenesis 2009, 30(12):2005-13. 10.1093/carcin/bgp244, 19825968.
2. Grothey A, Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 2009, 6(9):507-18. 10.1038/nrclinonc.2009.110, 19636328.
3. Johnson B, Osada T, Clay T, Lyerly H, Morse M. Physiology and therapeutics of vascular endothelial growth factor in tumor immunosuppression. Curr Mol Med 2009, 9(6):702-7. 10.2174/156652409788970634, 19689297.
4. Ribatti D. The seminal work of Werner Risau in the study of the development of the vascular system. Int J Dev Biol 2010, 54(4):567-72. 10.1387/ijdb.092892dr, 20209430.
5. Sung HK, Michael IP, Nagy A. Multifaceted role of vascular endothelial growth factor signaling in adult tissue physiology: an emerging concept with clinical implications. Curr Opin Hematol 2010, 17(3):206-12.
6. Greenberg JI, Cheresh DA. VEGF as an inhibitor of tumor vessel maturation: implications for cancer therapy. Expert Opin Biol Ther 2009, 9(11):1347-56. 10.1517/14712590903208883, 19761418.
7. Vecchiarelli-Federico LM, Cervi D, Haeri M, Li Y, Nagy A, Ben-David Y. Vascular endothelial growth factor--a positive and negative regulator of tumor growth. Cancer Res 2010, 70(3):863-7. 10.1158/0008-5472.CAN-09-3592, 20103650.
8. Di JM, Zhou J, Zhou XL, Gao X, Shao CQ, Pang J, Sun QP, Zhang Y, Ruan XX. Cyclooxygenase-2 expression is associated with vascular endothelial growth factor-C and lymph node metastases in human prostate cancer. Arch Med Res 2009, 40(4):268-75. 10.1016/j.arcmed.2009.03.002, 19608016.
9. Samaras V, Piperi C, Levidou G, Zisakis A, Kavantzas N, Themistocleous MS, Boviatsis EI, Barbatis C, Lea RW, Kalofoutis A, Korkolopoulou P. Analysis of interleukin (IL)-8 expression in human astrocytomas: associations with IL-6, cyclooxygenase-2, vascular endothelial growth factor, and microvessel morphometry. Hum Immunol 2009, 70(6):391-7. 10.1016/j.humimm.2009.03.011, 19332096.
10. Toomey DP, Murphy JF, Conlon KC. COX-2, VEGF and tumour angiogenesis. Surgeon 2009, 7(3):174-80. 10.1016/S1479-666X(09)80042-5, 19580182.
11. Ding C, Cicuttini F, Li J, Jones G. Targeting IL-6 in the treatment of inflammatory and autoimmune diseases. Expert Opin Investig Drugs 2009, 18(10):1457-66. 10.1517/13543780903203789, 19715447.
12. Hao Q, Wang L, Tang H. Vascular endothelial growth factor induces protein kinase D-dependent production of proinflammatory cytokines in endothelial cells. Am J Physiol Cell Physiol 2009, 296(4):C821-7. 10.1152/ajpcell.00504.2008, 19176759.
13. Kitadai Y. Cancer-Stromal Cell Interaction and Tumor Angiogenesis in Gastric Cancer. Cancer Microenviron 2009,
14. Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008, 14(21):6735-41. 10.1158/1078-0432.CCR-07-4843, 18980965.
15. Nishimoto N. Interleukin-6 in rheumatoid arthritis. Curr Opin Rheumatol 2006, 18(3):277-81. 10.1097/01.bor.0000218949.19860.d1, 16582692.
16. Dayer JM, Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology (Oxford) 2010, 49(1):15-24. 10.1093/rheumatology/kep329, 2789585, 19854855.
17. Ishizu A, Abe A, Miyatake Y, Baba T, Iinuma C, Tomaru U, Yoshiki T. Cyclic AMP response element-binding protein is implicated in IL-6 production from arthritic synovial cells. Mod Rheumatol 2010, 20(2):134-8. 10.1007/s10165-009-0245-2, 19921094.
18. Raj DS. Role of interleukin-6 in the anemia of chronic disease. Semin Arthritis Rheum 2009, 38(5):382-8. 10.1016/j.semarthrit.2008.01.006, 18336871.
19. Martin D, Galisteo R, Gutkind JS. CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex. J Biol Chem 2009, 284(10):6038-42. 10.1074/jbc.C800207200, 2649103, 19112107.
20. Rosenkilde MM, Schwartz TW. The chemokine system -- a major regulator of angiogenesis in health and disease. APMIS 2004, 112(7-8):481-95. 10.1111/j.1600-0463.2004.apm11207-0808.x, 15563311.
21. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link?. Biochem Pharmacol 2006, 72(11):1605-21. 10.1016/j.bcp.2006.06.029, 16889756.
22. Ono M. Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. Cancer Sci 2008, 99(8):1501-6. 10.1111/j.1349-7006.2008.00853.x, 18754859.
23. Porta C, Larghi P, Rimoldi M, Totaro MG, Allavena P, Mantovani A, Sica A. Cellular and molecular pathways linking inflammation and cancer. Immunobiology 2009, 214(9-10):761-77. 10.1016/j.imbio.2009.06.014, 19616341.
24. Takayama T, Goji T, Taniguchi T, Inoue A. Chemoprevention of colorectal cancer-experimental and clinical aspects. J Med Invest 2009, 56(1-2):1-5. 10.2152/jmi.56.1, 19262006.
25. de Haan LH, Pot GK, Aarts JM, Rietjens IM, Alink GM. In vivo relevance of two critical levels for NAD(P)H:quinone oxidoreductase (NQO1)-mediated cellular protection against electrophile toxicity found in vitro. Toxicol In Vitro 2006, 20(5):594-600. 10.1016/j.tiv.2005.10.005, 16314070.
26. Naumann R, Mayer D, Bannasch P. Voltammetric measurements of the kinetics of enzymatic reduction of 2, 6-dichlorophenolindophenol in normal and neoplastic hepatocytes using glucose as substrate. Biochim Biophys Acta 1985, 847(1):96-100. 10.1016/0167-4889(85)90158-2, 4052463.
27. Cabello CM, Bair WB, Bause AS, Wondrak GT. Antimelanoma activity of the redox dye DCPIP (2,6-dichlorophenolindophenol) is antagonized by NQO1. Biochem Pharmacol 2009, 78(4):344-54.
28. Debatin KM, Krammer PH. Death receptors in chemotherapy and cancer. Oncogene 2004, 23(16):2950-66. 10.1038/sj.onc.1207558, 15077156.
29. Strasser A, O'Connor L, Dixit VM. Apoptosis signaling. Annu Rev Biochem 2000, 69:217-45. 10.1146/annurev.biochem.69.1.217, 10966458.
30. Balan KV, Prince J, Han Z, Dimas K, Cladaras M, Wyche JH, Sitaras NM, Pantazis P. Antiproliferative activity and induction of apoptosis in human colon cancer cells treated in vitro with constituents of a product derived from Pistacia lentiscus L. var. chia. Phytomedicine 2007, 14(4):263-72. 10.1016/j.phymed.2006.03.009, 16713222.
31. Jaattela M. Multiple cell death pathways as regulators of tumour initiation and progression. Oncogene 2004, 23(16):2746-56. 10.1038/sj.onc.1207513, 15077138.
32. Lockshin RA, Zakeri Z. Caspase-independent cell death?. Oncogene 2004, 23(16):2766-73. 10.1038/sj.onc.1207514, 15077140.
33. Langer R, Folkman J. Polymers for the sustained release of proteins and other macromolecules. Nature 1976, 263(5580):797-800. 10.1038/263797a0, 995197.
34. Visscher GE, Robison RL, Maulding HV, Fong JW, Pearson JE, Argentieri GJ. Biodegradation of and tissue reaction to 50:50 poly(DL-lactide-co-glycolide) microcapsules. J Biomed Mater Res 1985, 19(3):349-65. 10.1002/jbm.820190315, 4077887.
35. Shive MS, Anderson JM. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 1997, 28(1):5-24. 10.1016/S0169-409X(97)00048-3, 10837562.
36. Jain RA. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 2000, 21(23):2475-90. 10.1016/S0142-9612(00)00115-0, 11055295.
37. Lathia JD, Leodore L, Wheatley MA. Polymeric contrast agent with targeting potential. Ultrasonics 2004, 42(1-9):763-8. 10.1016/j.ultras.2003.12.018, 15047380.
38. Park YJ, Nah SH, Lee JY, Jeong JM, Chung JK, Lee MC, Yang VC, Lee SJ. Surface-modified poly(lactide-co-glycolide) nanospheres for targeted bone imaging with enhanced labeling and delivery of radioisotope. J Biomed Mater Res A 2003, 67(3):751-60.
39. Mondalek FG, Ashley RA, Roth CC, Kibar Y, Shakir N, Ihnat MA, Fung KM, Grady BP, Kropp BP, Lin HK. Enhanced angiogenesis of modified porcine small intestinal submucosa with hyaluronic acid-poly(lactide-co-glycolide) nanoparticles: From fabrication to preclinical validation. J Biomed Mater Res A 2010,
40. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990, 82(13):1107-12. 10.1093/jnci/82.13.1107, 2359136.
41. Vistica DT, Skehan P, Scudiero D, Monks A, Pittman A, Boyd MR. Tetrazolium-based assays for cellular viability: a critical examination of selected parameters affecting formazan production. Cancer Res 1991, 51(10):2515-20.
42. Dimas K, Papadaki M, Tsimplouli C, Hatziantoniou S, Alevizopoulos K, Pantazis P, Demetzos C. Labd-14-ene-8,13-diol (sclareol) induces cell cycle arrest and apoptosis in human breast cancer cells and enhances the activity of anticancer drugs. Biomed Pharmacother 2006, 60(3):127-33. 10.1016/j.biopha.2006.01.003, 16527443.
43. Tamvakopoulos C, Dimas K, Sofianos ZD, Hatziantoniou S, Han Z, Liu ZL, Wyche JH, Pantazis P. Metabolism and anticancer activity of the curcumin analogue, dimethoxycurcumin. Clin Cancer Res 2007, 13(4):1269-77. 10.1158/1078-0432.CCR-06-1839, 17317839.
44. Dimas K, Hatziantoniou S, Tseleni S, Khan H, Georgopoulos A, Alevizopoulos K, Wyche JH, Pantazis P, Demetzos C. Sclareol induces apoptosis in human HCT116 colon cancer cells in vitro and suppression of HCT116 tumor growth in immunodeficient mice. Apoptosis 2007, 12(4):685-94. 10.1007/s10495-006-0026-8, 17260186.
45. Tufan AC, Satiroglu-Tufan NL. The chick embryo chorioallantoic membrane as a model system for the study of tumor angiogenesis, invasion and development of anti-angiogenic agents. Curr Cancer Drug Targets 2005, 5(4):249-66. 10.2174/1568009054064624, 15975046.
46. Brooks PC, Montgomery AM, Cheresh DA. Use of the 10-day-old chick embryo model for studying angiogenesis. Methods Mol Biol 1999, 129:257-69.
47. Subramaniam D, Ramalingam R, Betz J, Murali P, Houchen C, Anant S. A novel in vitro method to determine the bio-activity of phytochemicals in botanical extracts. Found Med Res 2006, 44-56.
48. Parchment RE. Programmed cell death (apoptosis) in murine blastocysts: extracellular free-radicals, polyamines, and other cytotoxic agents. In Vivo 1991, 5(5):493-500.
49. Elechiguerra JL, Burt JL, Morones JR, Camacho-Bragado A, Gao X, Lara HH, Yacaman MJ. Interaction of silver nanoparticles with HIV-1. J Nanobiotechnology 2005, 3:6. 10.1186/1477-3155-3-6, 1190212, 15987516.
50. Lara HH, Ayala-Nunez NV, Ixtepan-Turrent L, Rodriguez-Padilla C. Mode of antiviral action of silver nanoparticles against HIV-1. J Nanobiotechnology 2010, 8:1. 10.1186/1477-3155-8-1, 2818642, 20145735.
51. Chan JM, Valencia PM, Zhang L, Langer R, Farokhzad OC. Polymeric nanoparticles for drug delivery. Methods Mol Biol 2010, 624:163-75. full_text, 20217595.
52. Cherukuri P, Curley SA. Use of nanoparticles for targeted, noninvasive thermal destruction of malignant cells. Methods Mol Biol 2010, 624:359-73. full_text, 20217608.
53. Siddiqui IA, Adhami VM, Bharali DJ, Hafeez BB, Asim M, Khwaja SI, Ahmad N, Cui H, Mousa SA, Mukhtar H. Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate. Cancer Res 2009, 69(5):1712-6. 10.1158/0008-5472.CAN-08-3978, 19223530.
54. Wu Y, Wang W, Chen Y, Huang K, Shuai X, Chen Q, Li X, Lian G. The investigation of polymer-siRNA nanoparticle for gene therapy of gastric cancer in vitro. Int J Nanomedicine 2010, 5:129-36. 2841491, 20309399.
55. Clawson C, Huang CT, Futalan D, Martin Seible D, Saenz R, Larsson M, Ma W, Minev B, Zhang F, Ozkan M, Ozkan C, Esener S, Messmer D. Delivery of a peptide via poly(d, l-lactic-co-glycolic) acid nanoparticles enhances its dendritic cell-stimulatory capacity. Nanomedicine 2010,
56. Gao Y, Xu P, Chen L, Li Y. Prostaglandin E1 encapsulated into lipid nanoparticles improves its anti-inflammatory effect with low side-effect. Int J Pharm 2010, 387(1-2):263-71. 10.1016/j.ijpharm.2009.12.019, 20006690.
57. Goncalves DM, Chiasson S, Girard D. Activation of human neutrophils by titanium dioxide (TiO2) nanoparticles. Toxicol In Vitro 2010, 24(3):1002-8. 10.1016/j.tiv.2009.12.007, 20005940.
58. Gurunathan S, Lee KJ, Kalishwaralal K, Sheikpranbabu S, Vaidyanathan R, Eom SH. Antiangiogenic properties of silver nanoparticles. Biomaterials 2009, 30(31):6341-50. 10.1016/j.biomaterials.2009.08.008, 19698986.
59. Hueber AJ, Stevenson R, Stokes RJ, Graham D, Garside P, McInnes IB. Imaging inflammation in real time--future of nanoparticles. Autoimmunity 2009, 42(4):368-72. 10.1080/08916930902832298, 19811304.
60. Sheikpranbabu S, Kalishwaralal K, Venkataraman D, Eom SH, Park J, Gurunathan S. Silver nanoparticles inhibit VEGF-and IL-1beta-induced vascular permeability via Src dependent pathway in porcine retinal endothelial cells. J Nanobiotechnology 2009, 7:8. 10.1186/1477-3155-7-8, 2776000, 19878566.
61. Lo CT, Van Tassel PR, Saltzman WM. Poly(lactide-co-glycolide) nanoparticle assembly for highly efficient delivery of potent therapeutic agents from medical devices. Biomaterials 2010, 31(13):3631-42. 10.1016/j.biomaterials.2010.01.048, 20149428.
62. Nishiyama N. Nanomedicine: nanocarriers shape up for long life. Nat Nanotechnol 2007, 2(4):203-4. 10.1038/nnano.2007.88, 18654260.